

Cardiovascular Drugs: Global Markets to 2022

<https://marketpublishers.com/r/C83EDC8C7C1EN.html>

Date: March 2018

Pages: 174

Price: US\$ 1,375.00 (Single User License)

ID: C83EDC8C7C1EN

Abstracts

Report Scope:

This report provides detailed exposure of the cardiovascular drugs market, highlighting major cardiovascular diseases with detailed epidemiology for the primary disease areas. The report includes an industrywide assessment of the novel product launches, recent approvals, research and development pipeline, and blockbuster drugs.

Strict regulations are imposed on cardiovascular drugs and the report discusses the regional regulatory landscape for these drugs. This includes products approved by the regulatory authorities in recent years. Products under development or that are in different stages of clinical trials are analyzed in the pipeline assessment section.

Cardiovascular drug delivery systems are also included in the report, such as nanoparticle-mediated drug delivery, gene therapy and cell therapy, among others.

A discussion of the major players is included in the competitive landscape section, which looks at trends in product launches, collaborations, mergers and acquisitions, and other agreements. Company profiles of major players operating in the cardiovascular drugs market include overviews, key product offerings, financials, strategies, SWOT analysis, and new research and development strategies. The report will be particularly useful to readers in its thorough analysis of the leading products and will enable readers to recognize growing brands, key drug classes, and leading manufacturing companies with significant market share.

Report Includes:

52 data tables and 48 additional tables

An overview of the global market for cardiovascular drugs

Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022

A look at the regulatory environment, which has been a driving force in drug development

Information on competitor initiatives, and information with regard to demand for specialty chemicals used to develop new products and for new applications

Company profiles of the major players in the market, including Daiichi Sankyo Company Ltd., Johnson & Johnson, Novartis AG, AstraZeneca PLC, United Therapeutics Corp., Gilead Sciences Inc. and Pfizer Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MARKET DYNAMICS AND TECHNOLOGY BACKGROUND

Cardiovascular Drugs Market Definition and Overview
Epidemiology of Cardiovascular Diseases
Blockbuster Drugs
Market Drivers
Emergence of Effective Therapies for Hypertension and Hyperlipidemia
Increase in Aging Population
Government Regulations Improving Prescription Drug Assistance for the Elderly
Prevalence of Comorbidities Such as Diabetes and Obesity
Market Restraints
Lack of Incentives to Promote Cardiovascular Drug Development
Pricing Pressure Enforced on Manufacturers
High Cost Associated with New Drug Development and Clinical Trials
Patent Expiration of Blockbuster Drugs Leading to Wide Adoption of Generics
Market Opportunities
Focus on Prevention of Cardiovascular Disease
Emergence of Combination Therapy

CHAPTER 4 PIPELINE ANALYSIS

Research and Development Overview
Current Scenario of Cardiovascular Investments for Research and Development
Novel Drug Development/Approval

Promising Pipeline Molecules/Drugs in Development

CHAPTER 5 REGULATORY SCENARIO

Introduction

Regional Regulatory Landscape

North America

Europe

Asia-Pacific

Cardiovascular Drugs Approved

CHAPTER 6 CARDIOVASCULAR DRUG DELIVERY SYSTEMS

Introduction

Iontophoresis

Nanoparticle-Mediated Drug Delivery

Pericardiocentesis

Intracoronary Drug Delivery

Gene Therapy

Future Perspectives

CHAPTER 7 MARKET BREAKDOWN BY DISEASE AREAS

Disease Type

Hypertension

Hyperlipidemia

Thrombosis

Cardiac Failure Therapy

Stroke

Arrhythmias

Myocardial Infarction

Heart Failure

Acute Coronary Syndrome

Other Cardiovascular Diseases

Pulmonary Hypertension

Peripheral Artery Diseases

Inflammatory Heart Disease

Other Diseases

CHAPTER 8 MARKET BREAKDOWN BY DRUG CLASS

Introduction
Alpha-Blockers
Anti-Thrombotic (Anti-Coagulants and Anti-Platelets)
Lipid Lowering Agents
Anti-Hypertensives
Anti-Arrhythmic Drugs
Others

CHAPTER 9 MARKET BREAKDOWN BY REGION

North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Rest of Asia Pacific
Middle East and Africa
South America

CHAPTER 10 COMPETITIVE LANDSCAPE AND KEY DEVELOPMENTS

Major Players and Market Structure Analysis
Key Developments
Mergers and Acquisitions
New Product Launch
Agreement, Collaboration and Partnerships

CHAPTER 11 COMPANY PROFILES

AMGEN INC.

Company Overview

Financials

Product Information

Development and Strategies

ASTELLAS PHARMA INC.

Company Overview

Financials

Product Information

Development and Strategies

ASTRAZENECA PLC

Company Overview

Financials

Product Information

BRILINTA R (ticagrelor) tablets:

Crestor:

Development and Strategies

BOEHRINGER INGELHEIM GMBH

Company Overview

Financials

Product Information

Development and Strategies

BRISTOL-MYERS SQUIBB COMPANY

Company Overview

Financials

Product Information

Development and Strategies

DAIICHI SANKYO COMPANY LTD.

Company Overview

Financials

Product Information

Development and Strategies

ELI LILLY AND COMPANY

Company Overview

Financials

Product Information

Development and Strategies

GILEAD SCIENCES INC.

Company Overview

Financials

Product Information

Development and Strategies

GLAXOSMITHKLINE PLC

Company Overview

Financials

Product Information

Development and Strategies

HIKMA PHARMACEUTICALS PLC

Company Overview

Financials

Product Information

Development and Strategies

JOHNSON & JOHNSON INC.

Company Overview

Financials

Product Information

Development and Strategies

Product Information

MERCK & CO. INC.

Company Overview

Financials

Product Information

Development and Strategies

NOVARTIS AG

Company Overview

Financials

Product Information

Development and Strategies

PFIZER INC.

Company Overview

Financials

Product Information

Development and Strategies

SANOFI

Company Overview

Financials

Product Information
Development and Strategies
UNITED THERAPEUTICS CORP.
Company Overview
Financials
Product Information
Development and Strategies

CHAPTER 12 APPENDIX: ACRONYMS

Acronyms

List Of Tables

LIST OF TABLES

Summary Table A: Global Market for Cardiovascular Drugs, by Disease Area, Through 2022

Summary Table B: Global Market for Cardiovascular Drugs, by Drug Class, Through 2022

Summary Table C: Global Market for Cardiovascular Drugs, by Region, Through 2022

Table 1: Prevalence of High Blood Pressure, Age 18+, 2015

Table 2: List of Blockbuster Drugs, Manufacturer, 2014-2016

Table 3: Life Expectancy at Birth, Both Sexes Combined, by Region, 1990-2030

Table 4: Prevalence Rates for Adult Obesity, by Country, 2016

Table 5: Prevalence Rates of Australia Obesity for Male and Female, 1995-2015

Table 6: Cardiovascular Drugs Affected by the New Drug Price Control, Brand Name, Generic Name, Manufacturer

Table 7: Cardiovascular Drugs Going Off-Patent, 2016-2021

Table 8: Giapreza Snapshot

Table 9: Upravi Snapshot

Table 10: Invokana Snapshot

Table 11: Praluent Development Timeline

Table 12: Omecamtiv Mecarbil Developmental Pipeline

Table 13: AstraZeneca Plc. Cardiovascular Pipeline

Table 14: Amgen Inc. Cardiovascular Pipeline

Table 15: Pfizer Inc. Cardiovascular Pipeline

Table 16: Sanofi Cardiovascular Pipeline

Table 17: Novartis AG Cardiovascular Pipeline

Table 18: Merck and Co. Inc. Cardiovascular Pipeline

Table 19: Daiichi Sankyo Company, Ltd. Cardiovascular Pipeline

Table 20: Bristol-Myers Squibb Company Cardiovascular Pipeline

Table 21: Gilead Sciences Inc. Cardiovascular Pipeline

Table 22: Indicative List of Cardiovascular Drugs Approved by U.S. FDA and Health Canada (Brand Name, Manufacturer, Indication, Approval Date, and Approving Agency), 2015-2017

Table 23: Indicative List of Cardiovascular Drugs Approved by EMA (Brand Name, Manufacturer, Indication, and Approval Date), 2011-2016

Table 24: Cardiovascular Drugs Approved by PMDA (Brand Name, Manufacturer, Indication, and Approval Date), 2016-2017

Table 25: Indicative List of Cardiovascular Drugs Approved, U.S. FDA, EMA and DCGI

(Generic Name, Indication, Approval Year), 2006-2011

Table 26: Cardiovascular Drugs Approved (Brand Name, Generic Name, Approval Year, Manufacturer, and Indication), 2011-2016

Table 27: Global Cardiovascular Drugs Market, by Disease Area, Through 2022

Table 28: Classification of Hypertension or Blood Pressure

Table 29: Global Hypertension Market, by Region, Through 2022

Table 30: Recommended Cholesterol Levels

Table 31: Global Hyperlipidemia Market, by Region, Through 2022

Table 32: Global Thrombosis Market, by Region, Through 2022

Table 33: Global Cardiac Failure Therapy Market, by Region, Through 2022

Table 34: New York Heart Association Classification

Table 35: American Heart Association Classification

Table 36: Global Market for Other Cardiovascular Drugs, by Region, Through 2022

Table 37: Global Alpha-Blockers Market, by Region, Through 2022

Table 38: Global Anti-Thrombotic Market, by Region, Through 2022

Table 39: Global Lipid Lowering Agents Market, by Region, Through 2022

Table 40: Global Anti-Hypertensives Market, by Region, Through 2022

Table 41: Global Anti-Arrhythmic Drugs Market, by Region, Through 2022

Table 42: Global Anti-Arrhythmic Drug Classification, by Vaughan Williams Classification

Table 43: Global Market for Other Cardiovascular Drugs, by Region, Through 2022

Table 44: Global North American Cardiovascular Drugs Market, by Country, Through 2022

Table 45: European Cardiovascular Drugs Market, by Country, Through 2022

Table 46: Asia-Pacific Cardiovascular Drugs Market, by Country, Through 2022

Table 47: Global Cardiovascular Companies Ranking

Table 48: Patent Review, 2016-2017

Table 49: Repatha Snapshot

Table 50: Jardiance Snapshot

Table 51: Industry-wide Collaborations

Table 52: Amgen Net Revenue, 2015-2017

Table 53: Amgen Inc., Marketed Products, 2016

Table 54: Astellas Pharma Inc. Net Revenue, 2015-2017

Table 55: Astellas Pharma Inc. Marketed Products, 2017

Table 56: AstraZeneca PLC Net Revenue, 2014-2016

Table 57: AstraZeneca PLC Marketed Products, 2016

Table 58: AstraZeneca Global Cardiovascular Product Sales, 2014-2016

Table 59: Boehringer Ingelheim GmbH Net Revenue, 2014-2016

Table 60: Boehringer Ingelheim Marketed Products, by Indication, 2016

- Table 61: Boehringer Ingelheim GmbH Global Cardiovascular Product Sales, 2014-2016
- Table 62: Bristol-Myers Squibb Company Net Revenue, 2014-2016
- Table 63: Bristol-Myers Squibb Company Marketed Products, 2016
- Table 64: Daiichi Sankyo Company Ltd. Net Revenue, 2015-2017
- Table 65: Daiichi Sankyo Company Ltd. Marketed Products, by Indication, 2016
- Table 66: Eli Lilly and Company Net Revenue, 2014-2016
- Table 67: Eli Lilly and Company Marketed Products
- Table 68: Gilead Sciences Inc. Net Revenue, 2014-2016
- Table 69: Gilead Science Inc. Marketed Products
- Table 70: GlaxoSmithKline PLC Net Revenue, 2014-2016
- Table 71: GlaxoSmithKline PLC Marketed Products
- Table 72: Hikma Pharmaceuticals PLC Net Revenue, 2014-2016
- Table 73: Hikma Pharmaceuticals PLC Marketed Products
- Table 74: Johnson & Johnson Inc. Net Revenue, 2014-2016
- Table 75: Johnson & Johnson Inc. Marketed Products, 2016
- Table 76: Johnson & Johnson Inc. Marketed Products, by Indication, 2016
- Table 77: Merck & Co. Inc. Net Revenue, 2014-2016
- Table 78: Merck & Co. Inc. Marketed Products
- Table 79: Novartis AG Net Revenue, 2014-2016
- Table 80: Novartis AG Marketed Products by Indication, 2016
- Table 81: Pfizer Inc. Net Revenue, 2014-2016
- Table 82: Pfizer Inc. Marketed Products, by Indication, 2016
- Table 83: Sanofi Net Revenue, 2014-2016
- Table 84: Sanofi Marketed Products, by Indication, 2016
- Table 85: United Therapeutics Corp. Net Revenue, 2014-2016
- Table 86: United Therapeutics Corp. Marketed Products
- Table 87: Abbreviations Used in Cardiovascular Drug Market

List Of Figures

LIST OF FIGURES

- Summary Figure A: Global Market for Cardiovascular Drugs, by Disease Area, 2016-2022
- Summary Figure B: Global Market for Cardiovascular Drugs, by Drug Class, 2016-2022
- Summary Figure C: Global Market for Cardiovascular Drugs, by Region, 2016-2022
- Figure 1: Noncommunicable Diseases Mortality Share, by Cause of Death, 2015
- Figure 2: Top 10 Leading Causes of Death in the World, 2015
- Figure 3: Global Population Projection, Aged 60 and Above (Per 100,000 Persons)
- Figure 4: Global Population Projection, Aged 80 and Above (Per 100,000 Persons)
- Figure 5: United States Obesity, by State, 2016
- Figure 6: U.S. Generic Drug Savings, 2005-2014
- Figure 7: Likelihood of Approval from Phase I, by Disease Area
- Figure 8: The Center for Drug Evaluation and Research, by Therapeutic Area, 2017
- Figure 9: Cardiovascular Drugs Approval Process, U.S. FDA and EMEA
- Figure 10: Approved Indications for the Most Prevalent Cardiovascular Diseases, by the U.S. FDA and Health Canada, 1980-2014
- Figure 11: China CFDA Drug Regulatory Approval Process
- Figure 12: Japan PMDA Drug Regulatory Approval Process
- Figure 13: Global Cardiovascular Disease Rates for Countries with Least Age-Standardized Mortality, 2015 (Per 100,000 Persons)
- Figure 14: Global Cardiovascular Disease Rates for Countries with Highest Age-Standardized Mortality, 2015 (Per 100,000 Persons)
- Figure 15: Global Cardiovascular Drugs Market, by Disease Area, 2016-2022
- Figure 16: Global Hypertension Market, by Region, 2016-2022
- Figure 17: Global Hyperlipidemia Market, by Region, 2016-2022
- Figure 18: Global Thrombosis Market, by Region, 2016-2022
- Figure 19: Global Cardiac Failure Therapy Market, 2016-2022
- Figure 20: Global Cardiac Failure Therapy Market, by Region, 2016-2022
- Figure 21: Global Stroke Mortality, Per 100,000
- Figure 22: Global Market for Other Cardiovascular Disease, 2016-2022
- Figure 23: Global Market for Other Cardiovascular Drugs, by Region, 2016-2022
- Figure 24: Global Alpha-Blockers Market, 2016-2022
- Figure 25: Global Alpha-Blockers Market, by Region, 2016-2022
- Figure 26: Global Anti-Thrombotic Market, 2016-2022
- Figure 27: Global Anti-Thrombotic Market, by Region, 2016-2022
- Figure 28: Global Lipid Lowering Agents Market, 2016-2022

- Figure 29: Global Lipid Lowering Agents Market, by Region, 2016-2022
- Figure 30: Global Anti-Hypertensives Market, 2016-2022
- Figure 31: Global Anti-Hypertensives Market, by Region, 2016-2022
- Figure 32: Global Anti-Arrhythmic Drugs Market, 2016-2022
- Figure 33: Global Anti-Arrhythmic Drugs Market, by Region, 2016-2022
- Figure 34: Global Market for Other Cardiovascular Drugs, by Region, 2016-2022
- Figure 35: Global Cardiovascular Deaths, by Region (Per 100,000 Persons) 2015 and 2030 (F)
- Figure 36: Global North American Cardiovascular Drugs Market, 2016-2022
- Figure 37: United States' CVD Deaths Share, 2016
- Figure 38: United States Prevalence of Cardiovascular Disease Risk Factors, % of Adults
- Figure 39: Obese (Body Mass Index >30) and Overweight (Body Mass Index >25) Population
- Figure 40: Global North American Cardiovascular Drugs Market, by Country, 2016-2022
- Figure 41: Global North American Cardiovascular Drugs Market, by Disease Area, 2016-2022
- Figure 42: Global North American Cardiovascular Drugs Market, by Drug Class, 2016-2022
- Figure 43: Global European Cardiovascular Drugs Market, 2016-2022
- Figure 44: United Kingdom Mortality in Males, 2015
- Figure 45: United Kingdom Mortality in Females, 2015
- Figure 46: Leading Causes of Death in Italy and Percent Change, 2005-2016
- Figure 47: Spain Mortality in Women, 2014
- Figure 48: Spain Mortality in Men, 2014
- Figure 49: Leading Cause of Death in Europe, 2015
- Figure 50: Global European Cardiovascular Drugs Market, by Country, 2016-2022
- Figure 51: Global European Cardiovascular Drugs Market, by Disease Area, 2016-2022
- Figure 52: Global European Cardiovascular Drugs Market, by Drug Class, 2016-2022
- Figure 53: Asia-Pacific Population Data, by Age Group, 2016
- Figure 54: Asia-Pacific Population Data, by Age Group, 2022
- Figure 55: Asia-Pacific Cardiovascular Drugs Market, 2016-2022
- Figure 56: Singapore Causes of Death, by Cardiovascular Disease Type, 2014-2016
- Figure 57: Asia-Pacific Cardiovascular Drugs Market, by Country, 2016-2022
- Figure 58: Asia-Pacific Cardiovascular Drugs Market, by Disease Area, 2016-2022
- Figure 59: Asia-Pacific Cardiovascular Drugs Market, by Drug Class, 2016-2022
- Figure 60: Cardiovascular Mortality in Middle East and Africa Region, 2017
- Figure 61: Global Middle East and Africa Cardiovascular Drugs Market, 2016-2022
- Figure 62: Global Middle East and Africa Cardiovascular Drugs Market, by Disease

Area, 2016-2022

Figure 63: Global Middle East and Africa Cardiovascular Drugs Market, by Drug Class, 2016-2022

Figure 64: Global South American Cardiovascular Drugs Market, 2016-2022

Figure 65: Global South American Cardiovascular Drugs Market, by Disease Area, 2016-2022

Figure 66: Global South American Cardiovascular Drugs Market, by Drug Class, 2016-2022

Figure 67: Amgen Inc. Revenue Share, by Region, 2017

Figure 68: Amgen Inc. R&D Expenditure, 2014-2016

Figure 69: Astellas Pharma Inc. Revenue Share, by Region, 2017

Figure 70: Astellas Pharma Inc. R&D Expenditure, 2015-2017

Figure 71: AstraZeneca PLC Revenue Share, by Region, 2016

Figure 72: AstraZeneca PLC Revenue Share, by Business Segment, 2016

Figure 73: AstraZeneca PLC R&D Expenditure, 2014-2016

Figure 74: Boehringer Ingelheim GmbH Revenue Share, by Region, 2016

Figure 75: Boehringer Ingelheim GmbH Revenue Share, by Business Segment, 2016

Figure 76: Boehringer Ingelheim GmbH R&D Expenditure, 2014-2016

Figure 77: Bristol-Myers Squibb Company Revenue Share, by Region, 2016

Figure 78: Bristol-Myers Squibb Company Revenue Share, by Business Segment, 2016

Figure 79: Daiichi Sankyo Company Revenue Share, by Business Segment, 2016

Figure 80: Daiichi Sankyo R&D Expenditure, 2014-2016

Figure 81: Eli Lilly and Company Revenue Share, by Business Segment, 2016

Figure 82: Eli Lilly and Company Revenue Share, by Region, 2016

Figure 83: Gilead Sciences Inc. Revenue Share, by Business Segment, 2016

Figure 84: Gilead Sciences Inc. Revenue Share, by Region, 2016

Figure 85: GlaxoSmithKline PLC Revenue Share, by Business Segment, 2016

Figure 86: GlaxoSmithKline PLC Revenue Share, by Region, 2016

Figure 87: Hikma Pharmaceuticals PLC Revenue Share, by Business Segment, 2016

Figure 88: Hikma Pharmaceuticals PLC Revenue Share, by Region, 2016

Figure 89: Johnson and Johnson Inc. Revenue Share, by Business Segment, 2016

Figure 90: Johnson and Johnson Inc. Revenue Share, by Region, 2016

Figure 91: Merck & Co. Inc. Revenue Share, by Business Segment, 2016

Figure 92: Merck & Co. Inc. Revenue Share, by Region, 2016

Figure 93: Novartis AG Revenue Share, by Region, 2016

Figure 94: Novartis AG Revenue Share, by Business Segment, 2016

Figure 95: Pfizer Inc. Revenue Share, by Region, 2016

Figure 96: Pfizer Inc. Revenue Share, by Business Segment, 2016

Figure 97: Sanofi Revenue Share, by Region, 2016

Figure 98: Sanofi Revenue Share, by Business Segment, 2016

Figure 99: Sanofi R&D Expenditure, 2014-2016

I would like to order

Product name: Cardiovascular Drugs: Global Markets to 2022

Product link: <https://marketpublishers.com/r/C83EDC8C7C1EN.html>

Price: US\$ 1,375.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C83EDC8C7C1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970